New hope for stroke survivors with rare clotting disorder: rivaroxaban vs warfarin

NCT ID NCT03684564

Completed Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug rivaroxaban works as well as warfarin to prevent further brain damage in people who have had a stroke due to antiphospholipid syndrome (APS), a condition that causes abnormal blood clotting. About 40 participants took either rivaroxaban or warfarin for 24 months. The main goal was to see if brain scans showed less damage over time. This is a phase 2 trial, meaning it's an early test of effectiveness and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome brain infarction brain ischemia ischemic stroke stroke disorder systemic lupus erythematosus transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIPHOSPHOLIPID SYNDROME BRAIN ISCHEMIA ISCHEMIC STROKE STROKE SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Barts and the London Hospitals, Barts Health NHS Trust

London, United Kingdom
Epsom and St Helier University Hospitals NHS Trust

Epsom, United Kingdom
Hammersmith Hospital, Imperial College Healthcare NHS Trust

London, United Kingdom
Kings College Hospital NHS Foundation Trust

London, United Kingdom
Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust

Romford, United Kingdom
University College Hospitals NHS Foundation Trust

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.